Advanced

Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women - a Swedish Lymphoma Registry study.

Junlén, H R; Peterson, Stefan LU ; Kimby, E; Lockmer, S; Lindén, Ola LU ; Nilsson-Ehle, H; Erlanson, M; Hagberg, H; Rådlund, A and Hagberg, Oskar LU , et al. (2015) In Leukemia 29(3). p.668-676
Abstract
Treatment for follicular lymphoma (FL) improved with rituximab. In Sweden, first-line rituximab was gradually introduced between 2003 and 2007, with regional differences. The first national guidelines for FL were published in November 2007, recommending rituximab in first-line therapy. Using the population-based Swedish Lymphoma Registry, 2641 patients diagnosed with FL from 2000 through 2010 were identified and characterized by year and region of diagnosis, age (median, 65 years), gender (50% men), first-line therapy, and clinical risk factors. Overall and relative survival were estimated by calendar periods (2000-2002, 2003-2007, and 2008-2010) and region of diagnosis. With each period, first-line rituximab use and survival increased.... (More)
Treatment for follicular lymphoma (FL) improved with rituximab. In Sweden, first-line rituximab was gradually introduced between 2003 and 2007, with regional differences. The first national guidelines for FL were published in November 2007, recommending rituximab in first-line therapy. Using the population-based Swedish Lymphoma Registry, 2641 patients diagnosed with FL from 2000 through 2010 were identified and characterized by year and region of diagnosis, age (median, 65 years), gender (50% men), first-line therapy, and clinical risk factors. Overall and relative survival were estimated by calendar periods (2000-2002, 2003-2007, and 2008-2010) and region of diagnosis. With each period, first-line rituximab use and survival increased. Survival was superior in regions where rituximab was quickly adopted and inferior where slowly adopted. These differences were independent in multivariable analyses. Ten-year relative survival for patients diagnosed 2003-2010 was 92%, 83%, 78%, and 64% in the age groups 18-49, 50-59, 60-69, and ≥70, respectively. With increasing rituximab use, male sex emerged as an adverse factor. Survival improved in all patient categories, particularly in elderly women. The introduction and the establishment of rituximab have led to a nationwide improvement in FL survival. However, rituximab might be inadequately dosed in younger women and men of all ages.Leukemia accepted article preview online, 25 August 2014 doi:10.1038/leu.2014.251. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia
volume
29
issue
3
pages
668 - 676
publisher
Nature Publishing Group
external identifiers
  • pmid:25151959
  • wos:000350734300016
  • scopus:84924578405
ISSN
1476-5551
DOI
10.1038/leu.2014.251
language
English
LU publication?
yes
id
dedc2c17-5c1a-4fc9-8466-ea9e27dd1ca6 (old id 4614063)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25151959?dopt=Abstract
date added to LUP
2014-09-08 21:49:59
date last changed
2017-11-05 03:15:22
@article{dedc2c17-5c1a-4fc9-8466-ea9e27dd1ca6,
  abstract     = {Treatment for follicular lymphoma (FL) improved with rituximab. In Sweden, first-line rituximab was gradually introduced between 2003 and 2007, with regional differences. The first national guidelines for FL were published in November 2007, recommending rituximab in first-line therapy. Using the population-based Swedish Lymphoma Registry, 2641 patients diagnosed with FL from 2000 through 2010 were identified and characterized by year and region of diagnosis, age (median, 65 years), gender (50% men), first-line therapy, and clinical risk factors. Overall and relative survival were estimated by calendar periods (2000-2002, 2003-2007, and 2008-2010) and region of diagnosis. With each period, first-line rituximab use and survival increased. Survival was superior in regions where rituximab was quickly adopted and inferior where slowly adopted. These differences were independent in multivariable analyses. Ten-year relative survival for patients diagnosed 2003-2010 was 92%, 83%, 78%, and 64% in the age groups 18-49, 50-59, 60-69, and ≥70, respectively. With increasing rituximab use, male sex emerged as an adverse factor. Survival improved in all patient categories, particularly in elderly women. The introduction and the establishment of rituximab have led to a nationwide improvement in FL survival. However, rituximab might be inadequately dosed in younger women and men of all ages.Leukemia accepted article preview online, 25 August 2014 doi:10.1038/leu.2014.251.},
  author       = {Junlén, H R and Peterson, Stefan and Kimby, E and Lockmer, S and Lindén, Ola and Nilsson-Ehle, H and Erlanson, M and Hagberg, H and Rådlund, A and Hagberg, Oskar and Wahlin, B E},
  issn         = {1476-5551},
  language     = {eng},
  number       = {3},
  pages        = {668--676},
  publisher    = {Nature Publishing Group},
  series       = {Leukemia},
  title        = {Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women - a Swedish Lymphoma Registry study.},
  url          = {http://dx.doi.org/10.1038/leu.2014.251},
  volume       = {29},
  year         = {2015},
}